Abstract: Tissue ligation systems and methods are provides to mechanically strangulate abnormal or undesirable tissue. Tissue ligation systems include a multi-lumen catheter having an outer diameter smaller than the inner diameter of a standard endoscope channel such that the catheter can be inserted into the endoscope. Tissue ligation systems also include a ligation apparatus with an expandable hood disposed at the distal end of the catheter. A suture extends through a lumen of the catheter and has a distal loop portion that can strangulate tissue.

Abstract: Systems and methods are provided for providing a standardized pressure value representing a transient pressure event within a region of interest within a living body. An air-charged catheter is configured to record pressure data representing the region of interest. A measurement assembly includes a parameter calculation component configured to calculate at least a peak pressure representing the transient pressure event and a time to peak pressure, representing the time necessary to reach the peak pressure, from the recorded pressure data. A standardization component is configured to calculate the standardized pressure value as a function of the peak pressure and the time to peak pressure. A user interface is configured to display at least the standardized pressure value at an associated display.

Abstract: Sunscreen compositions comprising a dermatologically acceptable carrier and a polyhydroxy fullerene compound are described. The sunscreen compositions can be used to protect a substrate such as the skin of a subject from the effects of ultraviolet radiation.

Abstract: One aspect of the present disclosure can include a biocompatible tissue graft. The graft can include an extracellular matrix (ECM) patch or strip and at least one fiber stitched into the ECM patch or strip in a peripheral reinforcement pattern. The at least one fiber can have opposing terminal ends. The at least one fiber can mitigate tearing and/or improve fixation retention of the ECM patch or strip. The at least one fiber can comprise a plurality of interconnected stitches. The opposing terminal ends of the at least one fiber can be stitched together to form a continuous stitching construction.

Abstract: A computer-implemented method for determining the volume of activation of neural tissue. In one embodiment, the method uses one or more parametric equations that define a volume of activation, wherein the parameters for the one or more parametric equations are given as a function of an input vector that includes stimulation parameters. After receiving input data that includes values for the stimulation parameters and defining the input vector using the input data, the input vector is applied to the function to obtain the parameters for the one or more parametric equations. The parametric equation is solved to obtain a calculated volume of activation.

Abstract: A tissue collection and processing system for collecting bone fragments and tissue aspirated from a bone. The tissue collection and processing system includes a collection vessel, a collection vessel cap, a processing piston, a first tubing and a fluid withdrawal mechanism. The collection vessel has an opening formed therein to receive bone fragments and tissue aspirated from the bone. The collection vessel cap is capable of engaging the collection vessel to substantially seal the opening. The collection vessel cap or the collection vessel has a first port. The processing piston has an upper surface and a lower surface. The processing piston has a connection port and a bore. The connection port is proximate the upper surface. The bore is fluidly connected to the connection port and extends toward the lower surface. The processing piston has a density that is less than a density of fluid in the aspirated bone fragments and tissue.

Abstract: One aspect of the present disclosure relates to a system for treating obstructive sleep apnea in a subject. The system can include a power source and a neuromuscular stimulator in electrical communications with the power source. The neuromuscular stimulator can include a controller and at least one electrode. The controller can be configured to receive certain power and stimulation parameters associated with a therapy signal from the power source. The at least one electrode can be configured to deliver the therapy signal to a target tissue associated with control of a posterior base of the tongue of the subject.

Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

Abstract: A surgical device for implanting an artificial cornea into an eye can comprise an installation tool comprising an implantation end for receiving a back portion of an artificial cornea. The installation tool can further comprise a drive nut positioned above the implantation end. The surgical device can further comprise a thumbscrew that is received within the drive nut. The thumbscrew can be rotatable relative to the drive nut to adjust a position of the thumbscrew. During an implantation procedure, the implantation end with the back portion of the artificial cornea positioned thereon can be inserted into the eye, and the thumbscrew can be rotated relative to the drive nut to interact against a front portion of the artificial cornea to lock the artificial cornea in place.

Abstract: The effects of acute toxicity from a radiation procedure can be reduced without altering the radiation dose. Instead, a radiation procedure can be weighted to deliver certain amounts of radiation per day through temporal feathering. A target volume for a radiation procedure can be determined based on at least one image. The radiation procedure includes a total dose of radiation to be administered in a time period. An organ outside of the target volume at risk of acute toxicity from the radiation procedure can be determined based on the at least one image. A sequence plan that ensures the total dose of radiation is administered in the time period can be calculated. The sequence plan includes one day of a high fractional dose of radiation and four days of a low fractional dose of radiation. The sequence accomplishes temporal feathering of the radiation therapy procedure.

Abstract: A cryo-fixation lead extraction device includes a lead extraction catheter having longitudinally spaced proximal and distal catheter ends and an elongate catheter lumen. A liner has longitudinally spaced proximal and distal liner ends and an elongate liner lumen. The liner lumen is configured to selectively accept at least part of a lead being extracted longitudinally therethrough. At least a portion of the liner is located circumferentially within and/or circumferentially surrounding the catheter lumen. At least one cryogen supply line extends longitudinally through at least a portion of the liner lumen. The cryogen supply line is configured to place a cryogen fluid source into fluid communication with the distal liner end. The cryogen supply line is configured to selectively generate a patient tissue cooled zone adjacent the distal catheter end. A method of cryo-fixation lead extraction is also provided.

Abstract: A blood pump (10) includes a pump housing (30) having a pump inlet (16) and a pump outlet (18) spaced apart along a longitudinally extending central pump axis (28). The blood pump (10) also includes a rotating assembly (100) comprising an impeller (104). The blood pump (10) further includes partial arc journal bearings (160, 180) that support the rotating assembly (100) for rotation in the housing (30). The rotating assembly (100) is rotatable relative to the housing (30) to pump blood from the pump inlet (16) to the pump outlet (18).

Abstract: A method of treating cancer is described. The method includes administering a therapeutically effective amount of a TET2 activating compound or pharmaceutically acceptable salt thereof to a subject in need of treatment. The TET2 activating compounds are ?-ketoglutarate derivatives. A method of treating or preventing cancer in a subject that includes the step of analyzing a biological sample to determine if cells of the biological sample exhibit a TET2 mutation in addition to administering a TET2 activator is also described.

Abstract: Neural stimulation is provided according to a closed loop algorithm to treat sleep disordered breathing (SOB), including obstructive sleep apnea (OSA). The closed loop algorithm is executed by a system comprising a processor (which can be within the neural stimulator). The closed loop algorithm includes monitoring physiological data (e.g., EMG data) recorded by a sensor implanted adjacent to an anterior lingual muscle; identifying a trigger within the physiological data, wherein the trigger is identified as a biomarker for a condition related to sleep (e.g., inspiration); and applying a rule-based classification (which can learn) to the trigger to determine whether one or more parameters of a stimulation should be altered based on the biomarker.

Abstract: This disclosure describes systems and methods for electrocardiographic waveform analysis, data presentation and actionable advisory generation. Electrocardiographic waveform data can be received from a wearable device associated with a patient. A mathematical analysis can be performed on the electrocardiographic waveform data to provide cardiac analytics. A visualization of the cardiac analytics on a dashboard display can be generated. A value can be based on a comparison of the cardiac analytics to at least one baseline value for the patient; and a decision of whether or not to generate an actionable advisory for the electrocardiographic waveform data can be made based on the value. When the actionable advisory is generated, the actionable advisory is sent to one or more medical professionals, where it can be modified, and displayed with the visualization of the cardiac analytics.

Abstract: This disclosure relates to a device to mechanically and electrically connect with a touch screen computing device, such as a tablet computer. The device can include a platform that can be moved into and out of physical contact with a surface of a touch screen. During engagement with the surface, the moveable platform electrically interacts with the touch screen (e.g., via capacitive coupling) to enable detection by the touch screen of contact members (e.g., pegs) even in the absence of user contact with the pegs.

Abstract: A bone void filler preparation system that includes a processing vessel, a processing piston, a bone void filler preparation container and tubing. The processing vessel has a recess formed therein. The processing vessel is adapted to receive bone marrow aspirate. The processing piston includes an outer wall, a central wall member and a connection port. The outer wall has an upper edge and a lower edge. The central wall member extends inwardly from the outer wall intermediate the upper and lower edges of the processing piston. The central wall member has an aperture formed therein. The central wall member has a downwardly directed portion that defines an air-retaining region. The air-retaining region is closer to the outer wall upper edge than the aperture. The connection port is operably connected to the aperture. The processing piston is movable in the processing vessel recess. The bone void filler preparation container has an inlet portion and an outlet port.

Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

Abstract: Provided herein are compositions, articles of manufacture, food products, and methods for treating certain conditions, such as fibrotic disease (e.g., asthma). For example, in certain embodiments, provided herein are food products (e.g., that are ketogenic) that contain high levels (e.g., at least 10% by weight of the food product) of capric acid (C10), myristic acid (C14), or combination thereof (e.g., as free fatty acids or as triglycerides). In other embodiments, methods are provided for receiving an order for such a food product, and shipping the food product to a subject with fibrotic disease (e.g., after receiving or verifying prescription information). In some embodiments, methods are provided of administering or providing a composition to a subject such that the subject receives at least 50 grams per day (e.g., 200 grams per day), on multiple days, of capric acid (C10), myristic acid (C14), or combination thereof.